- In May 2023, Bayer announced that Larotrectinib sulfate is currently undergoing phase II clinical trials, designed for the treatment of sarcoma with solid tumors in both adults and children
- In June 2023, CancerVAX, Inc., the developer of a revolutionary universal cancer vaccine that utilizes the immune system to combat cancer, launched a $10 million financing round. The funds raised through an SEC-approved Reg A+ sale will help advance its groundbreaking cancer treatments. The company is collaborating with UCLA to develop targeted therapies for Ewing sarcoma, an aggressive cancer affecting young individuals' bones and soft tissues
- In March 2022, Phio Pharmaceuticals Corp., a biotechnology firm specializing in immuno-oncology drugs based on its self-delivering RNAi therapeutic platform, announced a partnership with AgonOx, Inc. The collaboration aims to develop cancer drugs by combining AgonOx’s tumor-infiltrating T-cell technology with Phio’s RNAi platform
- In January 2021, Pfizer announced that the European Commission had approved Vitrakvi (larotrectinib) for the treatment of advanced soft tissue sarcoma. Vitrakvi is a targeted therapy for patients whose malignancies contain a specific genetic mutation
- In June 2021, Johnson & Johnson revealed that its drug JNJ-4528 had been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma. Though not specifically for soft tissue sarcoma, JNJ-4528 is a CAR-T cell therapy being developed for various malignancies, including certain types of sarcoma
